Financing, Medical device

Second Sight secures $32 million IPO

Posted on 24 November 2014

Tags: , ,

Second Sight Medical Products secured it pricing of its initial public offering of 3,500,000 shares of common stock, at a price of $9.00 per share.

Second Sight develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients.

Its current product, the Argus II System, which treats outer retinal degenerations such as retinitis pigmentosa, is the only retinal prosthesis approved in the United States by the FDA and the first approved retinal prosthesis in the world.

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

 

Print Friendly, PDF & Email

Leave a Reply